These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34513923)

  • 1. The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.
    Torres S; Brol MJ; Magdaleno F; Schierwagen R; Uschner FE; Klein S; Ortiz C; Tyc O; Bachtler N; Stunden J; Bertheloot D; Kitanovic A; Sanchez B; Schrum J; Roush WR; Franchi L; Byth K; Latz E; Trebicka J
    Front Mol Biosci; 2021; 8():715765. PubMed ID: 34513923
    [No Abstract]   [Full Text] [Related]  

  • 2. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
    Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
    Kaufmann B; Kui L; Reca A; Leszczynska A; Kim AD; Booshehri LM; Wree A; Friess H; Hartmann D; Broderick L; Hoffman HM; Feldstein AE
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):751-767. PubMed ID: 35787975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid.
    Cai C; Zhu X; Li P; Li J; Gong J; Shen W; He K
    Inflammation; 2017 Dec; 40(6):1875-1883. PubMed ID: 28730512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation.
    Yang ZY; Liu F; Liu PH; Guo WJ; Xiong GY; Pan H; Wei L
    Int J Clin Exp Pathol; 2017; 10(8):8119-8129. PubMed ID: 31966664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis.
    Schierwagen R; Maybüchen L; Zimmer S; Hittatiya K; Bäck C; Klein S; Uschner FE; Reul W; Boor P; Nickenig G; Strassburg CP; Trautwein C; Plat J; Lütjohann D; Sauerbruch T; Tacke F; Trebicka J
    Sci Rep; 2015 Aug; 5():12931. PubMed ID: 26263022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
    Liu J; Wang T; He K; Xu M; Gong JP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway.
    Deng YF; Xu QQ; Chen TQ; Ming JX; Wang YF; Mao LN; Zhou JJ; Sun WG; Zhou Q; Ren H; Zhang YH
    Phytomedicine; 2022 Sep; 104():154241. PubMed ID: 35749827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loganin Prevents Hepatic Steatosis by Blocking NLRP3 Inflammasome Activation.
    Jang JH; Yang G; Seok JK; Kang HC; Cho YY; Lee HS; Lee JY
    Biomol Ther (Seoul); 2023 Jan; 31(1):40-47. PubMed ID: 36111592
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yen IC; Lin JC; Chen Y; Tu QW; Lee SY
    Am J Chin Med; 2020; 48(8):1859-1874. PubMed ID: 33308101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
    Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
    Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation.
    Wang X; Gao Y; Song J; Tang C; Wang M; Que L; Liu L; Zhu G; Chen Q; Yao Y; Xu Y; Li J; Li Y
    Br J Pharmacol; 2017 Jun; 174(12):1841-1856. PubMed ID: 28306139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation.
    Inia JA; Stokman G; Pieterman EJ; Morrison MC; Menke AL; Verschuren L; Caspers MPM; Giera M; Jukema JW; van den Hoek AM; Princen HMG
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.